- Home
- GENK vs TXMD Comparison
GENK vs TXMD Comparison
Compare GENK & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- TXMD
- Stock Information
- Founded
- GENK 2011
- TXMD 2008
- Country
- GENK United States
- TXMD United States
- Employees
- GENK N/A
- TXMD N/A
- Industry
- GENK Restaurants
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- TXMD Health Care
- Exchange
- GENK Nasdaq
- TXMD Nasdaq
- Market Cap
- GENK 20.4M
- TXMD 17.1M
- IPO Year
- GENK 2023
- TXMD N/A
- Fundamental
- Price
- GENK $3.73
- TXMD $1.18
- Analyst Decision
- GENK Strong Buy
- TXMD
- Analyst Count
- GENK 2
- TXMD 0
- Target Price
- GENK $10.00
- TXMD N/A
- AVG Volume (30 Days)
- GENK 105.8K
- TXMD 69.5K
- Earning Date
- GENK 07-30-2025
- TXMD 08-11-2025
- Dividend Yield
- GENK 0.82%
- TXMD N/A
- EPS Growth
- GENK N/A
- TXMD N/A
- EPS
- GENK N/A
- TXMD N/A
- Revenue
- GENK $214,957,000.00
- TXMD $1,841,000.00
- Revenue This Year
- GENK $16.62
- TXMD $427.09
- Revenue Next Year
- GENK $20.40
- TXMD N/A
- P/E Ratio
- GENK N/A
- TXMD N/A
- Revenue Growth
- GENK 14.40
- TXMD 53.55
- 52 Week Low
- GENK $3.16
- TXMD $0.70
- 52 Week High
- GENK $10.33
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- GENK 42.84
- TXMD 47.25
- Support Level
- GENK $3.50
- TXMD $1.11
- Resistance Level
- GENK $3.78
- TXMD $1.22
- Average True Range (ATR)
- GENK 0.26
- TXMD 0.09
- MACD
- GENK -0.01
- TXMD 0.00
- Stochastic Oscillator
- GENK 22.64
- TXMD 42.31
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.